US Drug Recall Register
Class II · Moderate risk Ongoing Initiated Dec 18, 2025 (9 months ago)

Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular…

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of particulate matter - Glass like particles.

What was recalled

Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.

Recalling firm
Imprimis NJOF, LLC
NDC code
71384-746-06
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0251-2026

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Triamcinolone recalls

See all